司美格鲁肽与2型糖尿病患者非动脉炎性前部缺血性视神经病变风险:观察性研究系统综述与荟萃分析
该系统综述与荟萃分析纳入5项观察性研究,评估2型糖尿病患者使用司美格鲁肽与NAION风险的关联。结果显示司美格鲁肽使用与NAION风险显著增加相关(HR 2.17,95%CI 1.73-2.74),但绝对风险低(0.014%),证据确定性低。
要点
- 司美格鲁肽使用与NAION风险增加相关,HR为2.17。
- 绝对风险低,约每年每7000例治疗患者增加1例NAION。
- 证据确定性低,需高质量研究进一步明确关联。
核心结论
- 司美格鲁肽使用可能与2型糖尿病患者NAION风险增加相关,但绝对风险低且证据确定性低。
研究设计与样本
- 系统综述与荟萃分析,纳入5项符合标准的观察性研究,另7项研究纳入敏感性分析。
主要发现
- 与不使用司美格鲁肽的降糖方案相比,司美格鲁肽使用与NAION风险显著增加相关(HR 2.17,95%CI 1.73-2.74;p<0.001)。
- 与排除其他GLP-1受体激动剂的方案相比,HR为2.13(95%CI 1.60-2.83;p<0.001)。
- 与SGLT2抑制剂使用者相比,HR为1.96(95%CI 1.28-2.99;p=0.002)。
- 绝对风险为0.014%(95%CI 0.005%-0.023%;p=0.002),相当于每年每7000例司美格鲁肽治疗患者约增加1例NAION。
关键数值与推荐
- 纳入标准为比较2型糖尿病年龄≥12岁患者使用司美格鲁肽与其他降糖治疗的观察性研究。
- 使用纽卡斯尔-渥太华量表和ROBINS-I v.2评估偏倚风险,采用GRADE框架分级证据确定性。
- 合并 hazard ratio(HR)和95%置信区间(CI)采用固定效应模型计算。
临床怎么用
- 临床医生应知晓司美格鲁肽使用可能与NAION风险增加相关,尤其对基线视神经病变风险较高的患者。
- 研究结果支持当前建议:对诊断为NAION的患者停用司美格鲁肽。
局限性
- 仅纳入回顾性、基于注册的观察性研究,证据合成受限。
- 可能存在研究水平的结果错误分类和混杂偏倚。
- 可用证据的确定性低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Semaglutide, a glucagon-like peptide-1 receptor agonist, is widely used for the management of type 2 diabetes (T2DM). Recent case reports have raised concerns about a potential association between semaglutide use and the development of nonarteritic anterior ischemic optic neuropathy (NAION), a rare but vision-threatening condition. We aimed to evaluate whether semaglutide use is associated with an increased risk of NAION in patients with T2DM. METHODS AND FINDINGS: We conducted a systematic review and meta-analysis of observational studies comparing patients with T2DM aged ≥12 years treated with semaglutide to those receiving other glucose-lowering therapies. We searched PubMed, Scopus, and Web of Science databases from January 2023 to November 2025. Two reviewers independently extracted data on study design, population characteristics, and outcomes. Risk of bias was assessed using the Newcastle-Ottawa Scale, and ROBINS-I v.2. Certainty of the evidence was graded according to the GRADE framework. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using fixed-effects models; sensitivity analyses included crude and subgroup HRs, and overlapping study replacement. Leave-one-out analysis was conducted to assess small-study effects and publication bias. Results were contextualized within other meta-analyses, systematic reviews, consensus statements, and regulatory communications on the topic. Five eligible observational studies met the inclusion criteria, and 7 additional studies were included in the sensitivity analysis. Semaglutide use was associated with a significantly increased hazard of NAION compared with nonsemaglutide glucose-lowering regimens (HR 2.17, 95% CI [1.73, 2.74]; p < 0.001), regimens excluding other GLP-1 receptor agonists (HR 2.13, 95% CI [1.60, 2.83]; p < 0.001), and sodium-glucose co-transporter 2 inhibitor (SGLT2i) users (HR 1.96, 95% CI [1.28, 2.99]; p = 0.002). Despite the increased relative risk, the absolute risk remained low at 0.014% (95% CI [0.005%, 0.023%]; p = 0.002), corresponding to approximately 1 additional case of NAION per 7,000 semaglutide-treated patients annually. The results were consistent with meta-analyses of observational studies and corroborated decisions presented in regulatory communications. Due to exclusive focus on retrospective, registry-based observational studies, the evidence synthesis was limited and could be biased by study-level outcome misclassification and confounding. CONCLUSIONS: Our findings suggest a possible association between semaglutide use and an increased risk of NAION in patients with T2DM. Although the absolute risk is low, clinicians should be aware of this potential adverse event, particularly in individuals at increased baseline risk for optic neuropathies. While these findings support current recommendations to discontinue semaglutide in patients diagnosed with NAION, the certainty of the available evidence is low, underscoring the need for further high-quality studies to clarify this association.
引用
- Chrzanowski J, Walicka M, Burzyński J, et al. Semaglutide-associated risk of nonarteritic anterior ischemic optic neuropathy in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies. PLoS Med. 2026. PMID: 42166479. doi:10.1371/journal.pmed.1005064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。